Synovial sarcoma
Aug 12, 2024
TECELRA Approval for Synovial Sarcoma Treatment – A Ray of Hope
Adaptimmune Therapeutics and patients waiting for synovial sarcoma treatment witnessed a historic moment at the start of this month. After over ten years without new synovial sarcoma treatments, a groundbreaking, first-in-class cell therapy, TECELRA (afamitresgene autoleucel) has been approved by the FDA. This a...
Read More...
Aug 06, 2024
Tecelra by Adaptimmune: First FDA-Approved Engineered Cell Therapy for Solid Tumors; GSK’s JEMPERLI Approved for Endometrial Cancer; MBX Biosciences Secures $63.5M in Series C for PEP™ Platform; FDA Stops Actinium’s Radiotherapy Blood Cancer Plans, Pushing Partnering Shift; Otsuka Acquires Jnana for Up to $1.1B, Enhancing Drug Discovery
Adaptimmune’s TECELRA Becomes First FDA-Approved Engineered Cell Therapy for Solid Tumors Adaptimmune Therapeutics announced that the FDA has approved (afamitresgene autoleucel), which will be marketed under the brand name TECELRA, for the treatment of unresectable or metastatic synovial sarcoma. This marks the ...
Read More...
Feb 06, 2024
4DMT Presents Data From Phase II PRISM Clinical Trial; Adaptimmune Announces FDA Acceptance of Biologics License Application for Afami-cel; Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA; AnaMar Announces US and EU Orphan Drug Designation for AM1476; Biosyngen Announces FDA Fast Track Designation for BST02; Acepodia Announces FDA Clearance of IND Application for ACE2016
4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...
Read More...
Mar 05, 2021
Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’?
Cancer is often challenging, however, diagnosis of rare cancer poses extra difficulties. Of all the diagnosed cancers, approximately 22% of the cases are rare cancers. According to the US National Cancer Institute, a cancer rare cancers as those with an incidence of fewer than 15 cases per 100 000 per year. Rare...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
